^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
AC699
i
Other names: AC699
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Accutar Biotech
Drug class:
Estrogen receptor alpha degrader
Related drugs:
6ms
AC699-001, a first in human Phase 1 trial utilizing a novel estrogen receptor chimeric degrader in patients with advanced or metastatic breast cancer (SABCS 2023)
Modulation of estrogen activity with therapeutics such as tamoxifen and aromatase inhibitors have been the mainstay therapeutic strategy for ER-positive breast cancer. Several ER-directed therapies have been developed to antagonize the oncogenic ER function, including Selective ER Degraders (SERDs) such as fulvestrant which is approved to treat patients with advanced or metastatic breast cancer...Enrollment began in December 2022 with five sites in the United States planned. NCT05654532.
Clinical • P1 data • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • EGFR positive
|
tamoxifen • fulvestrant • AC699
over1year
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
P1, N=60, Recruiting, Accutar Biotechnology Inc | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive
|
AC699
over1year
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
P1, N=60, Not yet recruiting, Accutar Biotechnology Inc
New P1 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive
|
AC699
Share via
